Q3172387 (Q3172387): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Created claim: summary (P836): The overall objective of MicroMarker project research and development of new ingredients, functional foods and healthy nutritional supplements that include active ingredients capable of modulating the microbiota when it is subjected to or causes alterations associated with chronic inflammation and oxidative stress during natural processes such as ageing or pathological processes (fibromyalgia, CRC), to alterations affected by the intestinal-brai...) |
||||||||||||||
| Property / summary | |||||||||||||||
The overall objective of MicroMarker project research and development of new ingredients, functional foods and healthy nutritional supplements that include active ingredients capable of modulating the microbiota when it is subjected to or causes alterations associated with chronic inflammation and oxidative stress during natural processes such as ageing or pathological processes (fibromyalgia, CRC), to alterations affected by the intestinal-brain axis (autism, migraine)._x000D_ For this purpose new biomarkers will be defined that can be used as indicators of well-being and health, based on microbiota patterns and their correlation with other clinical bioindicators. Healthy microbiota patterns will be defined on the basis of studies in preclinical models and clinical trials, which will analyse qualitatively and quantitatively the strangle of bacterial communities at the gender or species level), and study their correlation with inte-tinal metabolism, gut-brain signalling and other basic clinical biomarkers. Of particular importance is the fact that preclinical models will work with animals with humanised microbiota from volunteers. Therefore, preclinical and clinical trials will be based on common microbiota patterns, reinforcing the value and applicability of mouse trials. This innovative approach will allow to define new biomarkers and their mechanisms of action, which will allow to associate a certain pattern in the microbiota with specific physiological alterations, some of them sub-clinical, within the same population group or in a sub-population (with/without inflammation, with/without malnutrition...). (English) | |||||||||||||||
| Property / summary: The overall objective of MicroMarker project research and development of new ingredients, functional foods and healthy nutritional supplements that include active ingredients capable of modulating the microbiota when it is subjected to or causes alterations associated with chronic inflammation and oxidative stress during natural processes such as ageing or pathological processes (fibromyalgia, CRC), to alterations affected by the intestinal-brain axis (autism, migraine)._x000D_ For this purpose new biomarkers will be defined that can be used as indicators of well-being and health, based on microbiota patterns and their correlation with other clinical bioindicators. Healthy microbiota patterns will be defined on the basis of studies in preclinical models and clinical trials, which will analyse qualitatively and quantitatively the strangle of bacterial communities at the gender or species level), and study their correlation with inte-tinal metabolism, gut-brain signalling and other basic clinical biomarkers. Of particular importance is the fact that preclinical models will work with animals with humanised microbiota from volunteers. Therefore, preclinical and clinical trials will be based on common microbiota patterns, reinforcing the value and applicability of mouse trials. This innovative approach will allow to define new biomarkers and their mechanisms of action, which will allow to associate a certain pattern in the microbiota with specific physiological alterations, some of them sub-clinical, within the same population group or in a sub-population (with/without inflammation, with/without malnutrition...). (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The overall objective of MicroMarker project research and development of new ingredients, functional foods and healthy nutritional supplements that include active ingredients capable of modulating the microbiota when it is subjected to or causes alterations associated with chronic inflammation and oxidative stress during natural processes such as ageing or pathological processes (fibromyalgia, CRC), to alterations affected by the intestinal-brain axis (autism, migraine)._x000D_ For this purpose new biomarkers will be defined that can be used as indicators of well-being and health, based on microbiota patterns and their correlation with other clinical bioindicators. Healthy microbiota patterns will be defined on the basis of studies in preclinical models and clinical trials, which will analyse qualitatively and quantitatively the strangle of bacterial communities at the gender or species level), and study their correlation with inte-tinal metabolism, gut-brain signalling and other basic clinical biomarkers. Of particular importance is the fact that preclinical models will work with animals with humanised microbiota from volunteers. Therefore, preclinical and clinical trials will be based on common microbiota patterns, reinforcing the value and applicability of mouse trials. This innovative approach will allow to define new biomarkers and their mechanisms of action, which will allow to associate a certain pattern in the microbiota with specific physiological alterations, some of them sub-clinical, within the same population group or in a sub-population (with/without inflammation, with/without malnutrition...). (English) / qualifier | |||||||||||||||
point in time: 12 October 2021
| |||||||||||||||
Revision as of 18:46, 12 October 2021
Project Q3172387 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3172387 in Spain |
Statements
383,693.5 Euro
0 references
767,387.0 Euro
0 references
50.0 percent
0 references
16 November 2017
0 references
31 October 2021
0 references
BIOPOLIS SL
0 references
39°30'14.11"N, 0°26'31.56"W
0 references
46190
0 references
El objetivo general de proyecto MicroMARKER la investigación y desarrollo de nuevos ingredientes, alimentos funcionales y complementos nutricionales saludables que incluyan ingredientes activos capaces de modular la microbiota cuando esté some-tida o sea causa de alteraciones asociadas a inflamación crónica y estrés oxidativo durante procesos naturales como el envejeci-miento o en procesos patológicos (fibromialgia, CRC), a alteraciones afectadas por el eje intestino-cerebro (autismo, migraña)._x000D_ Para ello se definirán nuevos biomarcadores que puedan ser empleados como indicadores de bienestar y salud, en base a los patrones de microbiota y su correlación con otros bioindicadores clínicos. Los patrones de microbiota saludable se definirán en base a estudios en modelos preclínicos y ensayos clínicos, en los que se analizará de manera cualitativa y cuantitativa la estrucura de las comunidades bacterianas a nivel de género y/o especie), y se estudiará su correlación con el metabolismo intes-tinal, la señalización intestino-cerebro y otros biomarcadores clínicos básicos. Es de especial relevancia el hecho de que en los mo-delos preclínicos se trabajará con animales con microbiota humanizada procedente de voluntarios. Por lo tanto, ensayos preclíni-cos y clínicos partirán de patrones de microbiota comunes, lo que refuerza el valor y la aplicabilidad de los ensayos en rato-nes. Esta aproximación innovadora permitirá definir nuevos biomarcadores y sus mecanismos de acción, que permitirán asociar un determinado patrón en la microbiota con unas alteraciones fisiológicas concretas, algunas de ellas sub-clínicas, dentro de un mismo grupo poblacional o en una sub-población (con/sin inflamación, con/sin malnutrición…). (Spanish)
0 references
The overall objective of MicroMarker project research and development of new ingredients, functional foods and healthy nutritional supplements that include active ingredients capable of modulating the microbiota when it is subjected to or causes alterations associated with chronic inflammation and oxidative stress during natural processes such as ageing or pathological processes (fibromyalgia, CRC), to alterations affected by the intestinal-brain axis (autism, migraine)._x000D_ For this purpose new biomarkers will be defined that can be used as indicators of well-being and health, based on microbiota patterns and their correlation with other clinical bioindicators. Healthy microbiota patterns will be defined on the basis of studies in preclinical models and clinical trials, which will analyse qualitatively and quantitatively the strangle of bacterial communities at the gender or species level), and study their correlation with inte-tinal metabolism, gut-brain signalling and other basic clinical biomarkers. Of particular importance is the fact that preclinical models will work with animals with humanised microbiota from volunteers. Therefore, preclinical and clinical trials will be based on common microbiota patterns, reinforcing the value and applicability of mouse trials. This innovative approach will allow to define new biomarkers and their mechanisms of action, which will allow to associate a certain pattern in the microbiota with specific physiological alterations, some of them sub-clinical, within the same population group or in a sub-population (with/without inflammation, with/without malnutrition...). (English)
12 October 2021
0 references
Paterna
0 references
Identifiers
IDI-20180484
0 references